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alone was without effect but in combination with IFN-gamma mark-
edly impaired the ability of the long-acting beta-agonist to phospho-
rylate CREB. This suggests a novel mechanism whereby IFN-gamma 
interferes with beta-agonist signaling by impairing phosphorylation 
of CREB. This may be important in reducing the responses to beta-
agonists in refractory asthma.
Conclusion: IFN-gamma interferes with beta-2 agonist signaling 
by impairing phosphorylation of CREB. This may be important in 
reducing the responses to beta-agonists in refractory asthma.
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Introduction: Ulcerative colitis is an inflammatory chronic disease 
primarily affecting the colonic mucosa; the extent and severity of 
colon involvement are variable. The cause of UC remains unknown. 
However, some findings recently point to an overstimulation or inad-
equate regulation of the mucosal immune system as a major patho-
physiologic pathway. The role of angiotensin-converting enzyme 
blockers or angiotensin receptor blockers in the possible modulation 
of colon inflammation had not been verified. This prompted us to 
assess and compare the possible protective and therapeutic effects of 
captopril and valsartan on the extent and severity of ulcerative colitis 
induced by acetic acid in rats and to study the possible underlying 
mechanism of action of these drugs.
Patients (or Materials) and Methods: Seventy male Wistar albino 
rats were used. The animals were randomly divided into 7 groups 
each of 10 rats. Group 1: Normal control group, received Arabic 
gum PO 0.5 mlkg–1 (using gavage for all groups). Group 2: Acetic 
acid control group given 2 mL/rat 3% acetic acid rectally and Arabic 
gum PO for 2 weeks before induction of colitis. Group 3: Acetic acid 
control group 2 mL/rat 3% acetic acid rectally and Arabic gum PO 
for 2 weeks after induction of colitis. Group 4: Taken captopril HCl 
dissolved in Arabic gum at a dose of 30 mgkg-1 PO daily for 2 weeks 
before induction of ulcerative colitis. Group 5: Taken valsartan dis-
solved in Arabic gum at a dose of 30 mgkg-1 PO daily for 2 weeks 
before induction of ulcerative colitis. Group 6: Taken captopril HCl 
at a doses of 30 mgkg-1 PO once daily for 2 weeks after induction 
of UC. Group 7: Taken valsartan in a doses of 30 mgkg-1 PO once 
daily for 2 weeks after induction of ulcerative colitis.
Results: The results were assessed by histologic assessment of 
colonic tissues and measurement of malondialdehyde (MDA), tumor 
necrosis factor (TNF-α ), transforming growth factor (TGF-1b), 
angiotensin-converting enzyme (ACE), reduced glutathione (GSH), 
and platelet activating factor (PAF) levels in colonic tissues. Oral pre-
treatment with captopril or valsartan in a dose of 30 mgkg-1 body 
weight (prophylactic groups) and continuously for 2 weeks after 
induction (therapeutic groups) significantly reduce MDA, TNF-α , 
PAF, TGF-1b, and ACE levels in colonic tissues as compared with 
acetic acid control group. Also, a significant increase in GSH level 
was observed in colonic tissues. Captopril and valsartan attenu-
ated the macroscopic and microscopic colonic damage induced by 
acetic acid.
Conclusion: These results suggest that either captopril or valsar-
tan may be effective as prophylactic or treatment of UC through 
inhibition of ACE and scavenging effect on oxygen-derived free 
radicals.
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Introduction: Nonsteroidal anti-inflammatory drugs represent 1 of 
the most widely prescribed drugs used for treatment of pain and 
inflammation. The prescription of current existing anti-inflammatory 
drugs is hampered by their adverse effects over time. In the recent 
years, there is an upsurge in the areas related to newer developments 
in the prevention of disease especially the role of free radicals and 
antioxidants. Phenolic compounds are receiving increased attention 
as epidemiologic studies have highlighted the association between the 
consumption of polyphenolic–rich food and beverages and the pre-
vention of various human diseases. The present study investigated the 
analgesic and anti-inflammatory effects of chlorogenic acid (CGA), a 
polyphenolic compound present in many foods and beverages using 
carrageenan (Carr)-induced paw edema in rats and formalin – induce 
analgesia in mice.
Patients (or Materials) and Methods: Swiss mice (25–35 g) and 
Wistar rats (180–220 g), were used, chemicals and drugs (Formalin, 
Carrageenan, Indomethacin, CGA). Elisa Kits were used to study the 
effect of CGA on Carr-induced paw edema, 0.1 mL of 1% suspen-
sion of Carr in 0.9% Nacl solution was injected. The antinociceptive 
effects of CGA were tested by the formalin- induced hindpaw licking 
procedure in the day light. Elisa Kits were used to study the effects of 
CGA on some indices of oxidative stress. Reduced Glutathione and 
Malondialdehyde in paw tissues.
Results: Treatment of rats with CGA (50, 100, 150 mg/kg) signifi-
cantly reduced the rats paw edema induced by Carr and the formalin- 
induced pain in mice (P < 0.05) as compared with control groups. A 
significant reduction in rat paw volume in nitric oxide induced edema 
was observed (P < 0.05).CGA produced a significant reduction in 
malondialdehyde and significant increase in reduced glutathione in 
paw tissues (P < 0.05).
Conclusion: These results confirm that CGA has both analgesic and 
anti-inflammatory properties that may be related to the ability of 
this polyphenol to reduce the levels of superoxide and peroxynitrite 
anion radicals. CGA showed a promising potential drug of natural 
anti-inflammatory property to control oxidative stress.
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Introduction: The pharmacologic profile of antibodies to S100 pro-
tein (anti-S100) in release-active form has been studied since 1998. 
Animal studies revealed that they possess anxiolytic-like, antidepres-
sant-like, and neuroprotective activity. GABA-ergic system as well as 
sigma1 receptor are involved in the realization of their effects. The 
aim of the present study is to assess the influence of anti-S100 treat-
ment on the course of experimental allergic encephalomyelitis (EAE).
Patients (or Materials) and Methods: EAE was induced female 
Wistar rats (200–220 g) by a single subcutaneous inoculation of a 
spinal cord homogenate emulsified in complete Freund’s adjuvant 
(100 mg of homogenate of homologous spinal cord, 0.2 mL CFA, 
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and 0.2 ml of saline). The following substances were administered 
intragastrically 2 times a day at 7-hour intervals for 30 days start-
ing from the 1st day of EAE induction: anti-S100 (n = 20, 2.5 mL/
kg/d); distilled water (control; n = 20, 5 mL/kg/d). Reference drug 
(Glatiramer acetate, Copaxone®, Teva, Israel, n = 20) was adminis-
tered intramuscularly (4 mg/kg) from the 2nd to the 25th day after 
EAE induction.
Results: The severity of neurologic symptoms was assessed in points: 
muscle weakness, tremor (0.5 point); resistant paresis (1 point); 
paralysis (1.5 points). Clinical Index (CI) was calculated as a sum of 
the symptoms for 4 limbs. CI was defined as zero if visible clinical 
signs were absent, and as 6 in case of animal’s death. Cumulative 
index for each rat was calculated as a sum of individual CI for the 
total disease period (30 days). Time to disease onset (days) and the 
mean severity of the disease (points) were recorded in each group.
The key results of the study are presented in the Table.
Conclusion: Anti-S100 ameliorated clinical symptoms of EAE in 
Wistar rats: they both significantly reduced the severity of the disease 
and delayed the disease onset. The results give promise to patients in 
a search of a treatment option for multiple sclerosis.
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Introduction: In Sweden, some triptans became available over the 
counter (OTC) in 2008. The present study describes the utilization 
pattern of prescribed and OTC triptans in Sweden over time.
Patients (or Materials) and Methods: Wholesaler and aggregated 
sales data from the National Corporation of Swedish Pharmacies 
between 1991 and 2006, and patient identity data on dispensed pre-
scriptions between 2006 and 2010 from the National Prescribed 
Drug Register were used to investigate volume and expenditure of 
triptans over time. Prevalence was calculated for 2007 and 2011, 
measured as the number of patients/1000 inhabitants dispensed at 
least 1 triptan prescription. To illustrate proportions of patients dis-
pensed large and small amounts of the drug, respectively, Lorentz 
percentiles and Lorentz curves were used. Analyses were done by 
age and gender.
Results: Volumes of triptans sold has increased continuously to 
7.0 million defined daily doses (DDD) dispensed on prescriptions 
and 0.7 million DDDs OTCin 2011. The prevalence of triptan uti-
lization was 10.0 in 2007 and increased slightly to 10.1 in 2011. 
A marked gender difference was found with a 3.6 times higher 
prevalence of triptan use in women both years. The mean number of 
DDD increased with 10%, from 67 DDD per patient in 2007 to 74 
DDD per patient in 2011. The median volume per patient increased 
even more, 20%, from 30 DDD per patient in 2007 to 36 DDD 
per patient in 2011. Dispensed triptans were unevenly distributed 
within the population. In 2007, in women, 46% of the volume 
was purchased by 10% of those consuming the largest amounts. 
In men, the corresponding proportion consumed by 10% heavy 
users was 50%.
Conclusion: Triptans OTC has increased since the introduction as 
has the purchases of prescribed triptans. The number of patients 
dispensed triptans on prescription remained stable during the period 
studied even though the volumes increased.
Disclosure of Interest: None declared.
PP262—CaN auThoriTieS Take full 
adVaNTage of The aVailabiliTy of 
geNeriC aTyPiCal aNTiPSyChoTiC drugS? 
imPliCaTioNS for The fuTure
B. Godman1,2*; M. Persson3; J. Miranda4; C. Barbui5; M. 
Bennie2,6; K. Bennett7; A. Bucsics8; S. Simoens9; C. Zara10;  
and L.L. Gustafsson1
1Division of Clinical Pharmacology, Karolinska Institutet, 
Karolinska University Hospital, Stockholm, Sweden; 2Strathclyde 
Institute of Pharmacy and Biomedical Sciences, University of 
Strathclyde, Glasgow, United Kingdom; 3Drug Management 
Department; 4Department of Healthcare Development, 
Stockholm County Council, Stockholm, Sweden; 5WHO 
Collaborating Centre for Research and Training in Mental 
Health and Service Evaluation, Department of Public Health 
and Community Medicine, Section of Psychiatry, University of 
Verona, Verona, Italy; 6Information Services Division, NHS 
National Services Scotland, Edinburgh, United Kingdom; 
7Department of Pharmacology and Therapeutics, Trinity 
College, Dublin, Ireland; 8HVB, Vienna, Austria; 9Department 
of Pharmaceutical and Pharmacological Sciences, KU Leuven, 
Leuven, Belgium; and 10Barcelona Health Region, Catalan 
Health Service, Barcelona, Spain
Introduction: There could be an opportunity for health authorities 
to take advantage of oral generic atypical antipsychotic drugs (AAPs) 
given their considerable expenditure across countries. However, 
schizophrenia and bipolar disorders (BPD) are complex to treat, 
with the need to tailor treatments. Consequently, there is a need to 
assess changes in risperidone utilization before and after oral generic 
risperidone was reimbursed among European countries, as well as 
the utilization of generic versus originator risperidone, to provide 
future guidance.
Patients (or Materials) and Methods: We principally used an inter-
rupted time series design of monthly aggregated AAP utilization 
(2011 DDDs) up to 2 years before generic risperidone became avail-
able and reimbursed and up to 6 years after in Austria, Belgium, 
Ireland (GMS population), Scotland, Spain (Catalonia), and 
Sweden; (ii) Demand-side measures captured and categorised using 
the 4Es (Education, Engineering, Economics and Enforcement). 
Expenditure was also measured. Only administrative databases 
were used.
Results: There were generally no specific measures among the vari-
ous authorities to preferentially encourage the prescribing of oral 
Groups, 
the number 
of animals
Proportion 
of Animals 
With Symp-
toms
Severity of 
Symptoms
Time to Dis-
ease Onset, 
days
Mean 
Cumulative 
CI, Points 
(M ± m)
Mild, % Average, % Severe %
Control,  
n = 20
80 20 25 35 9.5 (8.0–
11.3)
27.53 ± 
7.19
Glatiramer 
acetate,  
n = 20
65 5 40 20 10.0 (9.0–
11.0)
18.03 ± 
6.20
Anti-S100, 
n = 20
85 40 40 5* 12.0 (8.0–
14.0)
18.96 ± 
5.94
⁎The difference with control is significant at P < 0.05 (chi-square test).
